Volume 67, Pages S52-S54 (January 2005)

Slides:

Advertisements

Similar presentations

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Early detection, prediction and potential treatment.

Advertisements

V.M. Campese, N. Mitra, D. Sandee Kidney International

Volume 55, Issue 2, Pages (February 1999)

Plasma sodium and hypertension

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Viper venom for diabetic nephropathy

Nat. Rev. Nephrol. doi: /nrneph

Anemia management in chronic kidney disease

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Epidemiology of diabetic nephropathy in Spain

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Volume 67, Issue 6, Pages (June 2005)

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Progression of renal failure and hypertensive nephrosclerosis

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Volume 81, Issue 7, Pages (April 2012)

Need for better diabetes treatment for improved renal outcome

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Volume 70, Pages S21-S25 (December 2006)

V.M. Campese, N. Mitra, D. Sandee Kidney International

Volume 55, Issue 2, Pages (February 1999)

Volume 57, Pages S32-S37 (April 2000)

Progression of diabetic nephropathy

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

The new role of calcimimetics as vasculotropic agents

Volume 63, Issue 2, Pages (February 2003)

Volume 82, Issue 3, Pages (August 2012)

Gary C.W. Chan, Sydney C.W. Tang Kidney International

The epidemiology of chronic kidney disease

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 65, Issue 6, Pages (June 2004)

Blood pressure targets in hemodialysis patients

Volume 361, Issue 9352, Pages (January 2003)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 67, Issue 1, Pages (January 2005)

Volume 53, Issue 4, Pages (April 1998)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

The future of renoprotection: Frustration and promises

Volume 87, Issue 1, Pages (January 2015)

Volume 84, Issue 5, Pages (November 2013)

The kidney, a cardiovascular risk marker, and a new target for therapy

Counteracting progression of renal disease: A look into the future

Volume 60, Issue 1, Pages (July 2001)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 87, Issue 1, Pages (January 2015)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Volume 53, Issue 6, Pages (June 1998)

Volume 67, Pages S3-S9 (January 2005)

Volume 55, Pages S3-S16 (June 1999)

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Volume 72, Issue 7, Pages (October 2007)

Is it the low-protein diet or simply the salt restriction?

Charles A. Herzog Kidney International

Volume 61, Issue 2, Pages (February 2002)

Volume 67, Issue 5, Pages (May 2005)

Volume 74, Issue 9, Pages (November 2008)

Volume 56, Issue 4, Pages (October 1999)

Volume 68, Issue 3, Pages (September 2005)

Renal vascular disease in the elderly

Volume 57, Issue 2, Pages (October 2000)

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Volume 54, Pages S112-S119 (December 1998)

Presentation transcript:

Volume 67, Pages S52-S54 (January 2005) Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria Andrew J. Palmer, Lieven Annemans, Stéphane Roze, Pablo Lapuerta, Roland Chen, Sylvie Gabriel, Paulo Carita, Roger A. Rodby, Dick de Zeeuw, Hans-Henrik Parving, Fernando De Alvaro Kidney International Volume 67, Pages S52-S54 (January 2005) DOI: 10.1111/j.1523-1755.2005.09312.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Mean number of years per patient spent in each disease state with either standard blood pressure control or irbesartan treatment. Control, standard antihypertensive medications excluding ACE inhibitors, other angiotensin II receptor antagonists, and dihydropyridine calcium channel blockers with equivalent blood pressure control. Irbesartan, standard antihypertensive medications plus 300mg irbesartan daily, started when patients have microalbuminuria. Kidney International 2005 67, S52-S54DOI: (10.1111/j.1523-1755.2005.09312.x) Copyright © 2005 International Society of Nephrology Terms and Conditions